» Articles » PMID: 28204831

Tachycardia-bradycardia Syndrome: Electrophysiological Mechanisms and Future Therapeutic Approaches (Review)

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2017 Feb 17
PMID 28204831
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Sick sinus syndrome (SSS) encompasses a group of disorders whereby the heart is unable to perform its pacemaker function, due to genetic and acquired causes. Tachycardia‑bradycardia syndrome (TBS) is a complication of SSS characterized by alternating tachycardia and bradycardia. Techniques such as genetic screening and molecular diagnostics together with the use of pre-clinical models have elucidated the electrophysiological mechanisms of this condition. Dysfunction of ion channels responsible for initiation or conduction of cardiac action potentials may underlie both bradycardia and tachycardia; bradycardia can also increase the risk of tachycardia, and vice versa. The mainstay treatment option for SSS is pacemaker implantation, an effective approach, but has disadvantages such as infection, limited battery life, dislodgement of leads and catheters to be permanently implanted in situ. Alternatives to electronic pacemakers are gene‑based bio‑artificial sinoatrial node and cell‑based bio‑artificial pacemakers, which are promising techniques whose long-term safety and efficacy need to be established. The aim of this article is to review the different ion channels involved in TBS, examine the three‑way relationship between ion channel dysfunction, tachycardia and bradycardia in TBS and to consider its current and future therapies.

Citing Articles

Shensong yangxin, a multi-functional traditional Chinese medicine for arrhythmia: A review of components, pharmacological mechanisms, and clinical applications.

Lu X, Wang T, Hou B, Han N, Li H, Wang X Heliyon. 2024; 10(16):e35560.

PMID: 39224243 PMC: 11367280. DOI: 10.1016/j.heliyon.2024.e35560.


Comparison between catheter ablation versus permanent pacemaker implantation as an initial treatment for tachycardia-bradycardia syndrome patients: a prospective, randomized trial.

Cho M, Lee J, Nam G, Hwang K, Cha M, Kim J BMC Cardiovasc Disord. 2024; 24(1):246.

PMID: 38730404 PMC: 11088091. DOI: 10.1186/s12872-024-03920-0.


Atrial fibrillation ablation compared to pacemaker therapy in patients with tachycardia-bradycardia syndrome: A systematic review and updated meta-analysis.

Su L, Wang X, Kang F, Gong C, Chen D Medicine (Baltimore). 2024; 103(16):e37543.

PMID: 38640303 PMC: 11030008. DOI: 10.1097/MD.0000000000037543.


Nine-Second Cardiac Arrest in a Patient With Anti-mitochondrial Antibody-Positive Myopathy Under General Anesthesia.

Kitaura A, Yamamoto R, Tsukimoto S, Hamasaki S, Nakajima Y Cureus. 2023; 15(4):e37436.

PMID: 37181956 PMC: 10174631. DOI: 10.7759/cureus.37436.


Metabolic rescue ameliorates mitochondrial encephalo-cardiomyopathy in murine and human iPSC models of Leigh syndrome.

Yoon J, Daneshgar N, Chu Y, Chen B, Hefti M, Vikram A Clin Transl Med. 2022; 12(7):e954.

PMID: 35872650 PMC: 9309541. DOI: 10.1002/ctm2.954.


References
1.
Schubert W, Spray D, Lisanti M . Connexin family members target to lipid raft domains and interact with caveolin-1. Biochemistry. 2002; 41(18):5754-64. DOI: 10.1021/bi0121656. View

2.
Yabek S, Jarmakani J . Sinus node dysfunction in children, adolescents, and young adults. Pediatrics. 1978; 61(4):593-8. View

3.
Kaplan B, LANGENDORF R, Lev M, Pick A . Tachycardia-bradycardia syndrome (so-called "sick sinus syndrome"). Pathology, mechanisms and treatment. Am J Cardiol. 1973; 31(4):497-508. DOI: 10.1016/0002-9149(73)90302-0. View

4.
FERRER M . The sick sinus syndrome in atrial disease. JAMA. 1968; 206(3):645-6. View

5.
Choy L, Yeo J, Tse V, Chan S, Tse G . Cardiac disease and arrhythmogenesis: Mechanistic insights from mouse models. Int J Cardiol Heart Vasc. 2016; 12:1-10. PMC: 5064289. DOI: 10.1016/j.ijcha.2016.05.005. View